CFTR and type 2 diabetes mellitus: CY-09, an analog of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor-172 (C172), blocks ATP binding with NLRP3 by directly binding to the NLRP3 Walker A motif, showing protective effects in mice models of gout and Types 2 diabetes.